1,534 trials (keyword fallback)
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Time to Failure — 16; 13 Days
Systemic Fungal Infections
Primary: Posaconazole Exposure Described as Area Under the Total Plasma Concentration-time Curve From Time Zero to Infinity After a Single Dose — 17932 ng*h/mL
Aspergillosis
Primary: Average of the Z-scores of the Time-Weighted Averages (TWA) of Fungal Biomarkers Galactomannan (GM) and (1,3)-β-D-glucan (βDG) Over the First Two Weeks of Treatment for…
Fungal Infection · Hematopoietic and Lymphoid Cell Neoplasm
Primary: 42-day-cumulative Incidence of Proven or Probable Invasive Fungal Infections (IFI) — 1.4; 1.4 percentage of patients
Fungal Infection
Primary: Single Dose Trough Concentration of IV Posaconazole (Cmin) — 318; 295; 467 ng/mL
Cytomegalovirus (CMV) Infections Among Children and Adult Liver Transplantation Patients in China
Primary: Number of Participants With Clinically Significant CMV Reactivation or CMV Disease — 62; 89; 78; 32 Participants
Otomycosis
Primary: Percentage of Subjects With Therapeutic Cure — 14; 11; 53; 53 Participants
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants
Central Line Fungal Infections
Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…
Fungal Infection
Primary: Steady State (ss) Average Concentration (Cavg) of Posaconazole of Serial PK (Subgroup 1) on Day 10 — 2986.28 ng/mL
Systemic Fungal Infections
Primary: Diagnosis of Systemic Fungal Infection (SFI) — 20; 6; 18; 3 Participants
Corneal Ulcer · Fungal Keratitis
Primary: Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus — 14; 11 Participants — p=0.26
Sick Sinus Syndrome · Complete Heart Block · Syncope
Primary: Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) Infection — 5; 6 Participants
Pulmonary Fungal Infection
Primary: Number of Participants With Clinical Efficacy — 8; 29; 18; 5 participants
Candidiasis, Vulvovaginal
Primary: Percentage of Subjects With Therapeutic Cure at 28 Days for All-Analysis Population — 9; 9; 11; 10 Participants